Last reviewed · How we verify
NCT04365114: POSTBOx
Patient Outcomes from Second Film-readers and Test Threshold Relaxation in Breast Screening
trial testing Breast Screening Mammography with single reader in Breast Cancer in 13,094,122 participants. Completed in 30 December 2024.
30 December 2024
Quick facts
| Lead sponsor | University of Warwick |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 13,094,122 |
| Start date | 1 October 2018 |
| Primary completion | 30 December 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Breast Screening Mammography with single reader
- Breast screening mammography with two readers
- Test threshold
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Ductal Carcinoma in Situ — all drugs for Ductal Carcinoma in Situ →
Sponsor
University of Warwick
Who can join
Adults 47 to 73, female only, with Breast Cancer or Ductal Carcinoma in Situ. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Analysis of women's medical records to understand the impact of previous changes to breast cancer screening (increase from one to two clinicians examining each woman's mammograms, and what proportion of women they recall for further tests)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04365114
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of Warwick trials
Trials by the same sponsor.
- NCT06334718 — Drone Delivered Defibrillators (The 3D Project). · completed
- NCT05402436 — Breast Screening Atypia and Subsequent Development of Cancer in England · completed
- NCT04977414 — Making Data Count Intervention Evaluation · NA · completed
- NCT05046197 — Evaluating the Integration of the Recommended Summary Plan for Emergency Care Treatment (ReSPECT) Into Primary Care · completed
- NCT05247463 — English Mammography Screening Outcomes by Age, Frequency and Test Threshold · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04365114 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Warwick
- Last refreshed: 24 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04365114.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing